- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - GSK/Vir Sotrovimab FDA Emergency Use Authorization
AnnouncementREG - GlaxoSmithKline PLC - Sanofi and GSK initiate new Phase 3 clinical study
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK/VIR sotrovimab receives positive EMA opinion
AnnouncementREG - GlaxoSmithKline PLC - Block listing Interim Review
AnnouncementREG - GlaxoSmithKline PLC - Medicago/GSK COVID-19 Vaccine Positive Ph2 Results
AnnouncementREG - GlaxoSmithKline PLC - Sanofi/GSK COVID-19 Vaccine Positive Ph2 Results
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSK Capital PLC - EMTN Prospectus
AnnouncementREG - GlaxoSmithKline PLC - EMTN Prospectus
AnnouncementREG - GlaxoSmithKline PLC - Board and Committee Changes
AnnouncementREG - Allianz Glbl Inv - Top 10 Holdings
AnnouncementREG - GlaxoSmithKline PLC - Result of AGM
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - 1st Quarter Results
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - EU approves GSK’s JEMPERLI (dostarlimab-gxly)
Announcement